deaths (OS)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus pemetrexed plus platin
nivolumab plus ipilimumab vs. pemetrexed plus platin 1 certainty unassessablestatistically conclusive-19%